Navigation Links
Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
Date:11/12/2007

w.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2006. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligation to publicly release the result of any revision to these forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
2. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
3. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
4. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Eisai Limited is ... introduction of the first-of-its-kind comic book available in ... has been designed specifically to educate children and their parents ... Canada affecting more than 300,000 Canadians. Eisai is ... care (hhc) , in which the patient is central – ...
(Date:8/21/2014)... Germany , Aug. 21, 2014  IBM (NYSE: ... Elektronen-Synchrotron ( DESY ), a leading national research center ... management and storage of massive volumes of x-ray data. ... based on IBM software defined technology can handle more ... performance and help scientists worldwide gain faster insights into ...
(Date:8/21/2014)... 2014 BreedIT Corp., (OTCQB: ... exclusive worldwide license holder and distributor of highly ... researchers, today is pleased to announce the formation ... Ltd, a leading Israeli medical Cannabis breeder. ... new breeds of medical Cannabis to meet the ...
Breaking Medicine Technology:Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4
... SAN DIEGO, June 16, 2011 Neurocrine Biosciences, Inc. ... elagolix presentations have been accepted for the scientific program ... September 4-7, 2011 in Montpellier, France. This important meeting ... every three years, bringing together clinicians and basic scientists ...
... 2011 Cebix Incorporated announced today it ... for the treatment of complications of diabetes. The biopharmaceutical ... evaluate Ersatta™, its proprietary long-acting form of C-peptide, in ... disease, lack this endogenous peptide.  Following the successful completion ...
Cached Medicine Technology:Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis 2Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis 3Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 2Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 3Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 4
(Date:8/22/2014)... Home Care Assistance of Centennial , North ... proud to announce the next installment in its renowned ... Dr. Suzanne Steinbaum, attending cardiologist and Director of Women’s ... City, National Spokesperson for the American Heart Association’s Go ... issues surrounding women and heart disease, what heart disease ...
(Date:8/22/2014)... -- College can be a challenging time for young people, ... to make the most of their new life, an expert ... new people and learn to manage the temptations of new ... at St. John,s University in New York City, said in ... in the classroom. College is a time when students transition ...
(Date:8/22/2014)... ItsHot.com, a client-centric manufacturer, wholesaler and ... on its range of beautiful diamond heart pendants. Customers ... Hearts 14K White Rose Gold Diamond Heart Pendant, which ... 77%. Previously priced at $3,715.00, customers can now buy ... of this mesmerizing pendant embedded with 0.66 carats round ...
(Date:8/22/2014)... According to the new research report "Isocyanate Market ... Forecast to 2019" defines and segments the isocyanate ... market value. The isocyanate material market value will ... significant CAGR from 2014 to 2019. , Browse ... through 286 pages and in-depth TOC on "Isocyanate ...
(Date:8/22/2014)... approx. 265,000 Danes are acutely admitted to medical departments ... University and Aarhus University Hospital now shows that many ... are sent home again without receiving a diagnosis ... hospitalisation., "Naturally, there is no need for a diagnosis ... is a serious illness. So some patients will always ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:College Prep 101 2Health News:ItsHot.com Now Offers 60-80% Discount on its Striking Collection of Diamond Heart Pendants 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 3Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 4Health News:Many patients are discharged without a diagnosis 2
... NHS hospital is, the higher the MRSA infection rate, research ... ,The impact of risk management standards on the frequency ... demanding risk management standards imposed by hospital insurers — and ... — could reduce MRSA infection rates. ,Institutions ...
... the US. Striking a blow for the pro-choice sections, New ... bill that would strengthen abortion rights. ,Only last ... Abortion Ban Act, signed by President Bush in 2003. The ... doctors say are often the safest and best to protect ...
... A team of researchers at the John Hopkins Hospital in the ... to the PSA to detect prostate cancer.// ,The new ... in a simple blood test. ,Prostate cancer, the ... areas of medicine. Physicians are unsure how to find it and ...
... little to maintaining one's health after all. A new UK study ... philosophically muse about flesh being heir to a thousand natural shocks, ... ,But the UK researchers point to a striking discrimination in the ... ages a person eight years earlier than high earners. ...
... food. That is a far more sensible way of fighting the ... , In fact prescription drugs to prevent diabetes cannot be ... ,Trials show rosiglitazone pills do work, but so does weight ... 2 diabetes, the researchers argue. ,In the British ...
... Research has shown a way for people suffering diabetic ... as alleviating the effects of diabetic retinopathy,// which is ... ,In the initial stages, retinopathy does not portray ... to cause the blood vessels of the eye to ...
Cached Medicine News:Health News:Better Risk Management Could Cut MRSA Infection Rates 2Health News:New York Governor to Introduce Bill to Strengthen Abortion Rights 2Health News:New blood test to detect prostate cancer 2Health News:Lower the wages, the faster one ages, UK study shows 2Health News:Lifestyle changes not prescription drugs to fight diabetes, say scientists 2
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: